Spots Global Cancer Trial Database for Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor
Official Title: Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor
Study ID: NCT03440515
Conditions
Interventions
Study Description
Brief Summary: To achieve optimal clinical outcomes with imatinib in GIST patients, it is crucial to maintain standard imatinib dose. Skin rash is a relatively common and sometimes severe adverse event of imatinib in GIST patients and may affect imatinib compliance. Our previous retrospective study suggested that severe skin rash induced by imatinib can be managed by systemic steroid without imatinib dose interruption or reduction. This phase II study was conducted to evaluate the efficacy and safety of systemic steroid in GIST patients with imatinib-associated severe skin rash.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Contact Details
Name: Yoon-Koo Kang, MD, PhD
Affiliation: Asan Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
